logo
Bay 'still recovering' from bottom trawling

Bay 'still recovering' from bottom trawling

Yahooa day ago

Part of the seabed off the Jurassic Coast is "still recovering" from the effects of bottom trawling 17 years after it was banned there, marine researchers have said.
A consultation is being held on government proposals to extend the ban on the practice of dragging large nets along the seafloor.
Some fishing organisations have criticised the plans and questioned the environmental impact of bottom trawling.
Dr Emma Sheehan, associate professor of marine ecology at Plymouth University said, ending bottom trawling when Lyme Bay, off the Dorset and Devon coast, became a Marine Protected Area in 2008 has made a "positive change".
The government proposal would expand the ban on bottom trawling from 18,000km2 to 48,000km2 (about 18,500 sq miles) of the UK's offshore areas that are already designated as protected.
A UN Ocean Conference is taking place in France amid warnings from Sir David Attenborough that bottom trawling is destroying areas of the seabed and marine life.
Researchers have studied the impact of ending bottom trawling in Lyme Bay since the introduction of the MPA.
Dr Sheehan said large areas of the bay had already been "heavily degraded" by 2008.
"[MPAs] tried to prevent the most destructive fishing methods so the seabed habitats that are so important for conservation and fisheries can be protected," she continued.
Dr Sheehan said species including scallops, conga eel and black sea bream and appeared to have benefited from the ban.
"We keep seeing positive change, year on year.
"We still haven't go a plateau in the recovery. We're nowhere near there - it's still recovering, year on year."
The government's plan would see similar protections extended to 41 of England's 181 MPAs.
"It needs to happen - I'm in full support of this and it will have huge positive benefits for our marine environment," Dr Sheehan said.
The UK's National Federation of Fishermen's Organisations has opposed the move to ban bottom trawling.
Chief executive Mike Cohen previously said: "Trawling does not damage most of the seabed.
"Trawls penetrate the sediment very little, if at all, in most areas and trawling has been carried out for well over 100 years," he said.
A 12-week consultation will run until 1 September and will seek the views of the marine and fishing industry.
You can follow BBC Dorset on Facebook, X (Twitter), or Instagram.
UK proposes wider ban on destructive ocean bottom trawling
Reef species increase in whole site management
University of Plymouth

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Star Trek: Strange New Worlds' renewed for fifth and final season
'Star Trek: Strange New Worlds' renewed for fifth and final season

Yahoo

time2 hours ago

  • Yahoo

'Star Trek: Strange New Worlds' renewed for fifth and final season

June 12 (UPI) -- Star Trek: Strange New Worlds will return for a fifth and final season, Paramount+ announced Thursday. The news arrives ahead of the July 17 premiere of Season 3. Filming is currently underway on Season 4. "From the very beginning, Strange New Worlds set out to honor what Star Trek has always stood for -- boundless curiosity, hope and the belief that a better future is possible. We're deeply grateful to Paramount+ for the chance to complete our five-season mission, just as we envisioned it, alongside our extraordinary cast and crew," said the show's executive producers, Akiva Goldsman, Henry Alonso Myers and Alex Kurtzman, in a statement. Season 3 will arrive on Paramount+ Aug. 4. View this post on Instagram A post shared by Star Trek (@startrek) Anson Mount will portray U.S.S. Enterprise Captain Pike in Season 3. Rebecca Romijn, Ethan Peck, Jess Bush, Christina Chong, Celia Rose Gooding, Melissa Navia, Babs Olusanmokun, Martin Quinn, Rhys Darby, Patton Oswalt, Cillian O'Sullivan, Melanie Scrofano, Carol Kande and Paul Wesley also star.

Bay 'still recovering' from bottom trawling
Bay 'still recovering' from bottom trawling

Yahoo

timea day ago

  • Yahoo

Bay 'still recovering' from bottom trawling

Part of the seabed off the Jurassic Coast is "still recovering" from the effects of bottom trawling 17 years after it was banned there, marine researchers have said. A consultation is being held on government proposals to extend the ban on the practice of dragging large nets along the seafloor. Some fishing organisations have criticised the plans and questioned the environmental impact of bottom trawling. Dr Emma Sheehan, associate professor of marine ecology at Plymouth University said, ending bottom trawling when Lyme Bay, off the Dorset and Devon coast, became a Marine Protected Area in 2008 has made a "positive change". The government proposal would expand the ban on bottom trawling from 18,000km2 to 48,000km2 (about 18,500 sq miles) of the UK's offshore areas that are already designated as protected. A UN Ocean Conference is taking place in France amid warnings from Sir David Attenborough that bottom trawling is destroying areas of the seabed and marine life. Researchers have studied the impact of ending bottom trawling in Lyme Bay since the introduction of the MPA. Dr Sheehan said large areas of the bay had already been "heavily degraded" by 2008. "[MPAs] tried to prevent the most destructive fishing methods so the seabed habitats that are so important for conservation and fisheries can be protected," she continued. Dr Sheehan said species including scallops, conga eel and black sea bream and appeared to have benefited from the ban. "We keep seeing positive change, year on year. "We still haven't go a plateau in the recovery. We're nowhere near there - it's still recovering, year on year." The government's plan would see similar protections extended to 41 of England's 181 MPAs. "It needs to happen - I'm in full support of this and it will have huge positive benefits for our marine environment," Dr Sheehan said. The UK's National Federation of Fishermen's Organisations has opposed the move to ban bottom trawling. Chief executive Mike Cohen previously said: "Trawling does not damage most of the seabed. "Trawls penetrate the sediment very little, if at all, in most areas and trawling has been carried out for well over 100 years," he said. A 12-week consultation will run until 1 September and will seek the views of the marine and fishing industry. You can follow BBC Dorset on Facebook, X (Twitter), or Instagram. UK proposes wider ban on destructive ocean bottom trawling Reef species increase in whole site management University of Plymouth

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

Yahoo

timea day ago

  • Yahoo

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store